Get to know our clinical trials
Clinical trial of Staccato® Alprazolam in study participants 12 years of age or older with prolonged stereotyped epileptic seizures
YOU ARE BEING INVITED TO PARTICIPATE IN THIS CLINICAL RESEARCH STUDY BECAUSE YOU HAVE A SPECIFIC TYPE OF EPILEPSY WITH PREVIOUS EPISODES OF PROLONGED SEIZURES AND HAVE PREVIOUSLY PARTICIPATED IN A PREVIOUS STUDY OF STACCATO® ALPRAZOLAM (I.E., EP0162, ENGAGE-E-001 OR UP0100). EPILEPSY IS A DISORDER OF THE CENTRAL NERVOUS SYSTEM IN WHICH BRAIN ACTIVITY BECOMES ABNORMAL, RESULTING IN SEIZURES OR PERIODS OF ABNORMAL BEHAVIOR OR SENSATIONS, AND SOMETIMES LOSS OF CONSCIOUSNESS. THE PURPOSE OF THIS STUDY IS TO EVALUATE THE LONG-TERM EFFECT AND SAFETY OF STACCATO® ALPRAZOLAM IN EPILEPTIC PATIENTS WITH PREVIOUS EPISODES OF PROLONGED SEIZURES, AS IN YOUR CASE.
Technical Summary
- OPEN-LABEL, MULTICENTER, OUTPATIENT, EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF STACCATO® ALPRAZOLAM IN STUDY PARTICIPANTS 12 YEARS OF AGE OR OLDER WITH PROLONGED STEREOTYPIC SEIZURES
- Code EudraCT: 2021-002637-42
- Protocol number: EP0165
- Promoter: UCB Biopharma SRL
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.